Skip to main navigation

Investors

Contact

Global Operations

North America

Canada
Mexico
USA

South America

Argentina
Brazil

Asia

China
Hong Kong
India
Japan
Korea
Singapore
Taiwan

Middle East

United Arab Emirates

Africa

South Africa

Australia

Australia New Zealand

Europe

Austria
Belgium Luxembourg
Czech Republic
Denmark
Finland
France
Germany
Greece
Ireland
Israel

Italy
Netherlands
Norway
Poland
Portugal
Russia
Spain
Sweden
Switzerland
Turkey
United Kingdom

Our Purpose
Mission and Core Values Partnerships and Community Advancing Global Health Giving Medication Access
About
Leadership Ethics and Code of Conduct U.S. Locations
Science & Medicine
Medicines Pipeline Research
News and Press
Press Room Company Statements Events Annual Report
Careers
Now Hiring Culture Diversity & Inclusion Benefits Internships
Utility
Privacy Statements Terms Of Use Social Media Guidelines EU Data Disclosure Sitemap

BACK TO MAIN MENU Partnerships and Community COMPASS Initiative Gilead Lift Gilead HIV Age Positively

BACK TO MAIN MENU Advancing Global Health HCV Elimination Ebola

BACK TO MAIN MENU Giving Grant Recipients Grant Funding Gilead Foundation Gilead Public Health Award

BACK TO MAIN MENU Medication Access U.S. Patient Access Disaster Product Replacement Global Access

BACK TO MAIN MENU Ethics and Code of Conduct Policies Global Transparency Anti-Counterfeiting Consumer Product Safety Supplier Info Authorized Distributors

BACK TO MAIN MENU Research Compassionate Use Investigator Sponsored Research Clinical Trials HIV/HCV No Co-Infection (NoCo) 2018 Program

BACK TO MAIN MENU Press Room Press Releases Press FAQS

BACK TO MAIN MENU Company Statements Discount For Ambisome Gilead 2017 Year in Review 100 Corporate Equality Score Emergency Disaster Response Gilead Year in Review 2016 Top Corporate Philanthropist HIV Medicines Reach 10 Million People Discover Study Of FTAF For PrEP Corporate Responsibility Report 2015 Gilead Supports PrEP Education Corporate Contributions Report Celebrating Transgender Awareness Week Kite Pharma Harnessing The Immune System Grants for SCLAN Authorized Generics For HCV

BACK TO MAIN MENU Annual Report 2017 Year in Review

BACK TO MAIN MENU Privacy Statements Cookie Statement Website Privacy Statement

BACK TO MAIN MENU Social Media Guidelines Linkedin Guidelines Twitter Guidelines

BACK TO MAIN MENU

North America

Canada
Mexico
USA

South America

Argentina
Brazil

Asia

China
Hong Kong
India
Japan
Korea
Singapore
Taiwan

Middle East

United Arab Emirates

Africa

South Africa

Australia

Australia New Zealand

Europe

Austria
Belgium Luxembourg
Czech Republic
Denmark
Finland
France
Germany
Greece
Ireland
Israel
Italy
Netherlands
Norway
Poland & The Baltics
Portugal
Russia
Spain
Sweden
Switzerland
Turkey
United Kingdom

BACK TO MAIN MENU

Contact

Request Medication Information
Information for Suppliers
Partnership Request

Investors
Contact
Global Operations

Toggle Inner Dropdown

BACK TO MAIN MENU Google.com

INVESTOR MENU

Investor Overview
Investor Fact Sheet
Press Releases
Corporate Governance
Stock Information
Financial & Filings
Events
Investor Resources

Investor Calendar

Third Quarter 2019 Gilead Sciences Earnings Conference Call

Oct 24, 2019 at 4:30 PM EDT

Click here for webcast

© 2018 Gilead. All rights reserved.

AREAS OF INTEREST

Site - Areas of Interest

Partnerships and Community
Pipeline
Medicines
Job Search

INFORMATION

Site - Information

Contact Us
Press Room
Investor Calls
Sitemap

LEGAL

Site - Legal

Privacy Policy
Terms of Use
EU Data Disclosure
Social Media Guidlines

FOLLOW US

Headline

Intersititial body copy

Ok Cancel